BioCentury
ARTICLE | Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

March 30, 2018 5:56 PM UTC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate to treat chronic pouchitis after a full review of PROPEL's interim data.

The company said a planned interim analysis by an IDMC determined the placebo-controlled trial to be futile based on data for the primary endpoint of Mayo score clinical remission in the first 65 patients who completed 12 weeks of treatment. PTG-100 is an oral integrin alpha(4)beta(7) antagonist...